Dynamic Contrast Enhanced Magnetic Resonance Imaging Parameters after Radiotherapy for Bone Metastases in Patients with Hepatocellular Carcinoma : A Prospective Study
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0004861
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Patients with hepatocellular carcinoma who were scheduled to
undergo radiation therapy for bone metastases were included. Patients were
included in the study if they were aged older than 18 years, had been diagnosed
to have hepatocellular carcinoma either by histological evaluation or clinical
imaging, and have been diagnosed to have metastases in thoracic, lumbosacral
vertebra, pelvic bone, or proximal femur. The criteria for considering bone
metastasis from hepatocellular carcinoma includes newly developed lesions, clear
progression of the lesion revealed from the follow-up examinations, or
histopathologic confirmation by bone biopsy if available.
Patients with history of another primary malignancy, history
of surgery, radiation therapy, or metallic instrumentation in thoracic,
lumbosacral spine, pelvic bone, or proximal femur, contraindication to
gadolinium-based contrast agents or MRI examinations, female patients who are
pregnant or nursing.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Volume transfer constant (Ktrans)
- Secondary Outcome Measures
Name Time Method constant rate (Kep), fractional volume of extracellular <br>extravascular space (Ve), blood plasma volume (Vp), apparent diffusion <br>coefficient (ADC), tumor volume;Treatment response based on MD Anderson criteria;time to symptom progression, time to local tumor progression, <br>overall survival